Carna Biosciences

(CBIXF, PINK)

$10.75

-$1.00
(-0.09%)
PE Ratio
16.96
EPS
$0.00
Market Cap
$165M
52 Week Range
$10.75 - $19.00
Operating Margin
0.00%
Dividend & Yield
$0.00 (0.00%)
Volume
NaN
Rev. per Share
$0.00

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.

Earnings

News about Carna Biosciences

Carna Biosciences

Type
Sector
Healthcare
Industry
Biotechnology
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView